Home ›
Breast Cancer Trials ›
NCT06318897
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.
Trial Details
NCT ID NCT06318897
Phase PHASE2
Sponsor M.D. Anderson Cancer Center
Status RECRUITING
Cancer Type Breast Cancer
Interventions Carboplatin Paclitaxel Pembrolizumab Doxorubicin Cyclophosphamide
Locations (sample) Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
Participants are eligible to be included in the study only if all of the following criteria apply: Participants must have histologically confirmed ER negative, PR negative and HER2-negative (TNBC) defined as ER\<10%, PR\<10%, and HER2 negative (p… AJCC 8 anatomic tumor Stage 1 T1b-T1c, N0, M0. All participants with clinically suspicious nodes must undergo core or fine needle biopsy per standa… Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of Stage 1…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →